8:36AM ISIS Pharm reports narrower than expected loss, beats on revs (ISIS) 14.23 : Reports Q4 (Dec) loss of $0.03 per share, $0.20 better than the Capital IQ Consensus Estimate of ($0.23); revenues fell 38.6% year/year to $19.9 mln vs the $15.29 mln consensus.
"We expect 2013 to be a year of substantial growth and maturation for Isis. We believe that the initial commercial launch of KYNAMRO will be successful and we support Genzyme's ongoing development efforts for KYNAMRO with the FOCUS FH study, which Genzyme is conducting under a special protocol assessment with the FDA... Beyond KYNAMRO, we have a number of drugs in our pipeline that will complete later-stage clinical studies, which are designed to provide clear evidence that these drugs have the potential to work in patients in numerous different diseases. In addition, we plan to advance many other drugs in our pipeline, creating additional opportunities for significant long-term revenue. And finally, we expect to explore partnering opportunities that are the right fit for Isis and designed to provide the most benefit to our programs and drugs, the best balance of risk and commercial participation, while allowing us to continue to do what we do best, drug discovery and early drug development."
Market Data 
Markets 
AI
